Sofinnova appoints Anderson as partner

Anderson has 25 years of experience in the healthcare and life sciences industries. Prior to joining Sofinnova, he was a partner at Abingworth, where he led venture capital investments in public companies and the formation of the firm's public equities fund.

Most recently, he was co-founder and CEO of Arix Bioscience, a venture capital firm listed on the London Stock Exchange.

Anderson also has experience as an active board member of several life sciences companies in the UK and the US. His investments have involved numerous private and public financing rounds, IPOs, M&As and exits.

Sofinnova is a European life-sciences-dedicated venture capital firm based in Paris, with offices in London and Milan.

The Sofinnova Crossover Fund is a €275m vehicle that focuses on late-stage private and public biopharmaceutical and medical device companies in Europe (80%) and North America (20%). The fund targets businesses with enterprise values of €50-150m and provides equity tickets of €15-20m, investing a maximum of €25m per company.

Earlier this year, Sofinnova held a final close on €108m for Sofinnova Telethon Fund, a vehicle dedicated to the Italian biotech sector, targeting companies that are developing cures for rare and genetic diseases.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• People
• France
• Southern Europe
• UK / Ireland
• people moves
• Sofinnova Partners
• France